Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ74856665 |
Synonyms | |
Therapy Description |
JNJ74856665 inhibits DHODH, which may lead to decreased proliferation and increased differentiation and apoptosis of cancer cells (Cancer Res 2021;81(13_Suppl):Abstract nr 1256). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ74856665 | JNJ-74856665|JNJ 74856665 | JNJ74856665 inhibits DHODH, which may lead to decreased proliferation and increased differentiation and apoptosis of cancer cells (Cancer Res 2021;81(13_Suppl):Abstract nr 1256). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04609826 | Phase I | JNJ74856665 Azacitidine + JNJ74856665 JNJ74856665 + Venetoclax | A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Active, not recruiting | GBR | FRA | ESP | 1 |